Submit your Defective Drugs claim details for a free, no obligation case review.
Get Started:
drug_recall crestorGovernment data suggests a strong link between Crestor and renal failure. Despite numerous studies indicating an increased risk for renal failure in Crestor users, neither the FDA nor AstraZeneca (Crestor’s maker) has taken any significant steps to protect consumers from these serious side effects. In 2005, an FDA expert listed Crestor as one of the top five most dangerous drugs on the market today. AstraZeneca maintains that their blockbuster cholesterol statin drug poses no greater health threat than other drugs of its kind, despite a wealth of evidence to the contrary.
Public Citizen, a reputable consumer advocacy group, has conducted numerous investigations of government medical data to determine the link between Crestor and renal failure. In 2003, before Crestor was even approved for use in the United States, Public Citizen formally presented scientific evidence of the link between Crestor and renal failure to the FDA. Medical experts presented evidence that Crestor posed a unique threat, greater than that posed by other statins, because of its unique kidney toxicity. In August 2003, the FDA approved this prescription medication, with minimal dosing limitations, despite understanding the strong link between Crestor and renal failure.
Clinical research and case studies have found that renal failure is 75 percent more likely in patients taking Crestor than people in the general population. While other medications of its class provide additional health benefits, such as protection against stroke and heart attack, Crestor provides no such benefits. At least 29 cases of Crestor and renal failure have been reported to the FDA and AstraZeneca, yet no steps have been taken to protect consumers. Many groups believe that allowing Crestor to remain on the market is a grossly negligent choice that poses a major threat to consumer well being.
Crestor and renal failure has also been linked to a serious, and potentially fatal, muscle condition called Rhabdomyolysis. Rhabdomyolysis is an acute and progressive condition that annihilates the muscles of the body, causing them to release their toxic constituents into the blood stream. This release of potassium and myoglobin into the blood from the destroyed muscles creates a dangerous imbalance in blood composition. Once this blood reaches the kidneys it can cause renal failure, other serious injuries, and even death.
When a person suffers the deadly effects of Crestor and renal failure, their kidneys are no longer able to perform their function of excreting wastes and balancing the body’s electrolytes. This can have a profoundly deleterious affect on the body. Early detection of the symptoms of renal failure is crucial to the patient’s survival. Some symptoms of Crestor and renal failure can include: decreased urination volume or output, increased urination at night, swelling, leg pain, changes in mood or mental awareness, seizures, bleeding or bruising easily, and more. If you are concerned about Crestor and renal failure or notice any unusual symptoms, you should speak with your doctor at your earliest convenience.
If you would like to learn more about your legal rights and options with regards to Crestor and renal failure, please contact us to speak with a qualified attorney.
The consumer advocacy group Public Citizen submitted a petition to the FDA a year ago asking the agency to immediately withdraw the anti-cholesterol drug Crestor, but the agency has denied its request.
Crestor belongs to a group of drugs ...
The FDA has announced that Crestor is being relabeled to add a warning that starter doses should be reduced in Asian-American patients, as well as some other higher risk patients.
A clinical trial found that levels in Asian patients were d...
The FDA announced a revised drug labeling for the cholesterol-lowering drug Crestor would be added, warning of the serious muscle damage called rhabdomyolysis.
A clinical trial found levels of Crestor in Asian patients were double those of C...